Idexx Laboratories financials
$533.44+0.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.14B | $1.09B | $1.11B | $1.11B | $998.4M | $954.3M | $975.5M | $1.00B | $964.1M | $901.6M | $915.5M |
| Gross profit | $779.1M | $722.7M | $658.1M | $683.4M | $694.7M | $623.4M | $570.7M | $596.0M | $619.2M | $593.1M | $526.2M | $548.0M |
| Gross margin | 64.0% | 63.4% | 60.3% | 61.8% | 62.6% | 62.4% | 59.8% | 61.1% | 61.7% | 61.5% | 58.4% | 59.9% |
| Operating income | $425.6M | $362.6M | $315.6M | $354.8M | $373.0M | $316.5M | $261.7M | $303.9M | $263.8M | $299.0M | $245.3M | $275.3M |
| Net income | $338.4M | $278.4M | $248.2M | $274.6M | $294.0M | $242.7M | $216.1M | $232.8M | $203.3M | $235.6M | $194.5M | $212.2M |
| Net margin | 27.8% | 24.4% | 22.8% | 24.8% | 26.5% | 24.3% | 22.7% | 23.9% | 20.3% | 24.4% | 21.6% | 23.2% |
| Diluted EPS | $4.27 | $3.47 | $3.08 | $3.40 | $3.63 | $2.96 | $2.62 | $2.80 | $2.44 | $2.81 | $2.32 | $2.53 |
| EBITDA | $466.6M | $400.3M | $354.3M | $391.5M | $408.8M | $350.6M | $295.4M | $338.0M | $296.0M | $328.9M | $245.3M | $304.3M |
| Operating cash flow | $347.2M | $266.2M | $355.8M | $402.3M | $185.7M | $238.0M | $262.0M | $220.1M | $248.3M | $198.6M | $249.9M | $272.4M |
| Free cash flow | $322.5M | $234.3M | $326.3M | $371.2M | $151.6M | $207.9M | $232.8M | $192.0M | $215.0M | $168.3M | $217.3M | $238.3M |
| Diluted shares | 79.3M | 80.2M | 80.5M | 80.7M | 81.0M | 81.9M | 82.6M | 83.1M | 83.4M | 84.0M | 84.0M | 84.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $196.9M | $200.5M | $180.1M | $208.2M | $164.6M | $164.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $968.9M | $979.9M | $847.8M | $979.8M | $1.10B | $940.2M |
| Total assets | $3.44B | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B |
| Total liabilities | $1.83B | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B |
| Shareholders' equity | $1.61B | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology